Carpenedo, M., Broome, C., González, B. S., McDonald, V., Miyakawa, Y., Nishiwaki, K., Zaja, F., Al-Samkari, H., Matthijssens, F., Chimits, D., Ayguasanosa, J., Raza, S., Monnickendam, G., Rodeghiero, F., Michel, M., Newland, A. (2025). Sustained improvements in patient-reported outcomes after intravenous efgartigimod in adults with primary immune thrombocytopenia in a Phase 3 clinical trial (ADVANCE IV) and the first 52 weeks in its open-label extension study (ADVANCE IV+). Blood. https://doi.org/10.1182/blood-2025-6245